C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
GDNSF Equity

GDNSF

OTCMKTS · GDNSF

$9.78
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 1/5
50/100 composite
Fundamentals66
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

Vireo Growth has been rated Neutral with a Composite score of 49.8 in the latest analysis. Within this band, fundamentals present the strongest pillar at 66.0, showing relative robustness compared to regulatory, market, and editorial pillars. The Neutral rating reflects low conviction at 1 out of 5, indicating a cautious stance driven by significant uncertainties. The Neutral classification suggests limited immediate upside potential, balanced by moderate strengths in financial parameters despite the cash runway's "stretched" condition.

Recent data depict a complex financial landscape for Vireo Growth. Year-over-year revenue growth registers at a healthy pace, while gross and operating margins indicate profitability hurdles due to elevated costs. However, a positive EBITDA amidst a net loss highlights efforts toward operational efficiency. The fundamental strengths are tempered by a broader backdrop of a "stretched" financial condition, emphasizing ongoing challenges in liquidity and solvency, which persist despite positive earnings before interest, taxes, depreciation, and amortization.

Looking forward, investors should monitor the fundamentals pillar closely, as it continues providing optimistic signals amidst challenges. Revenue growth and efficient margin management will remain key indicators to watch, as improvements here could eventually lead to a reevaluation of the financial condition. Any advancements in these areas could steer a shift in conviction, offering new directions in the company's financial trajectory.

Scored: 2026-08-24Valid through: 2026-10-08Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
Headquarters
209 South 9th St., Minneapolis, MN 55402
Phone
(844)484-7366
CEO
John Mazarakis
CFO
Tyson Macdonald
SEC CIK
0001771706
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$56.7M
Enterprise value
$141.2M
Price to book
1.22
Price to sales
0.61
EV / EBITDA
6.29
Revenue (TTM)
$93.1M
Gross profit (TTM)
$19.8M
EBITDA
$16.1M
Operating margin
19.8%
Profit margin
-25.6%
Rev growth YoY
26.2%
Return on equity
-1890.8%
Return on assets
5.3%
EPS (TTM)
$-0.17
EPS est. current year
$-0.12
Wall St. target price
$0.55
Shares outstanding
112.3M
Insider ownership
17.4%
Institutional ownership
15.3%
Beta
1.42
Full-time employees
385
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for GDNSF (GDNSF)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for GDNSF (GDNSF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for GDNSF are maintained by Cannabis Investor News and refreshed throughout the trading day.